Abstract
The calcium-channel blocking drugs have diverse chemical structures and, although the site and mechanism of their action has not been defined, they have been suggested to block voltage-dependent calcium channels by inhibiting transmembrane calcium influx through the cell membrane (1). The discovery of these drugs is a major development in cardiovascular pharmacology because their well-established ability to block excitation-contraction coupling in cardiac and vascular smooth muscle makes them useful in treating a wide variety of cardiovascular disorders. They also block excitation-secretion coupling and several other secretory processes that require calcium influx; however, they do so only at concentrations higher than those needed for blocking excitation-contraction coupling (2–6).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Fleckenstein A: Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Ann Rev Pharmacol Toxicol (17): 149–166, 1977.
Haeusler G: Differential effect of verapamil on excitation-contraction coupling in smooth muscle and on excitation-secretion coupling in adrenergic nerve terminals. J Pharmacol Exp Ther (180): 672–682, 1972.
Dreifuss JJ, Grau JD, Nordmann JJ: Effects on the isolated neurohypophysis of agents which affect the membrane permeability to calcium. J Physiol (London) (231): 96P–98P, 1973.
Russell JT, Thorn NA: Calcium and stimulus-secretion coupling in the neurohypophysis. II. Effects of lanthanum, a verapamil analogue (D-600) and prenylamine on 45-calcium transport and vasopressin release in isolated rat neurohypophysis. Acta Endocrinol (Copenhagen) (76): 471–487, 1974.
Malaisse WJ, Devis G, Pipeleers DG, Somers G: Calcium-antagonists and islet function. IV. Effect of D600. Diabetologia (12): 77–81, 1976.
Pinto JEB, Trifaro JM: The different effects of D-600 (methoxyverapamil) on the release of adrenal catecholamines induced by acetylcholine, high potassium or sodium deprivation. Br J Pharmacol (57): 127–132, 1976.
Chaudhry A, Vohra MM: A reserpine-like action of verapamil on cardiac sympathetic nerves. Eur J Pharmacol (97): 156–158, 1984.
Chaudhry A, Vohra MM: Depletion of cardiac noradrenaline stores by the calcium-channel blocker D-600. Can J Physiol Pharmacol In press, 1984.
Schöne H-H, Lindher E: Die Wirkungen des N-[3′-Phenyl-propyl-(2′)]-1, 1-diphenyl-propyl-(3)-amins auf den Stoffwechsel von Serotonin und Noradrenalin. Arzneimittel-Forsch (10): 583–585, 1960.
Schöne H-H, Lindner E: Über die Wirkung von N-(3′Pheny-propyl-(2′)-1, 1-diphenyl-propyl-(3)-amin auf den Katecholamin-Stoffwechsel. Klin Wochensch (40): 1196–1200, 1962.
Carlsson A, Hillarp NA, Waldeck B: Analysis of the Mg++-ATP dependent storage mechanism in the amine granules of the adrenal medulla. Acta Physiol Scand (59): [Suppl 215] 5–38, 1963.
McAllister RG, Howell SM: Fluorometric assay of verapamil in biological fluids and tissues. J Pharm Sci (65): 431–432, 1976.
Lüllmann H, Timmermans PBMWM, Ziegler A: Accumulation of drugs by resting or beating cardiac tissue. Eur J Pharmacol (60): 277–285, 1979.
Keefe DL, Kates RE: Myocardial disposition and cardiac pharmacodynamics of verapamil in the dog. J Pharmacol Exp Ther (220): 91–96, 1982.
Pang DC, Sperelakis N: Nifedipine, diltiazem, bepridil and verapamil uptakes into cardiac and smooth muscles. Eur J Pharmacol (87): 199–207, 1983.
Palm D, Grobecker H, Bak IJ: Membrane effects of catecholamine releasing drugs. In: Schumann HJ, Kroneberg G (eds) New aspects of storage and release mechanisms of catecholamines. (Bayer symposium II), Springer-Verlag, Berlin, 1970, pp 188–198.
Giachetti A, Shore PA: The reserpine receptor. Life Sci (23): 89–92, 1978.
Udenfriend S, Cooper JR., Clark CT, Baer JE: Rate of turnover of epinephrine in the adrenal medulla. Science (117): 663–665, 1953.
Mras S, Sperelakis N: Comparison of [3H]bepridil and [3H]verapamil uptake into rabbit aortic rings. J Cardiovas Pharmacol (4): 777–783, 1982.
Klevans LR, Gebber GL: Comparison of differential secretion of adrenal catecholamines by splanchnic nerve stimulation and cholinergic agents. J Pharmacol Exp Ther (172): 69–76, 1970.
Axelrod J, Hertling G, Patrick RW: Inhibition of H3-norepinephrine release by monoamine oxidase inhibitors. J Pharmacol Exp Ther (134): 325–328, 1961.
Kopin IJ: Biochemical aspects of release of norepinephrine and other amines from sympathetic nerve endings. Pharmacol Rev (18): 513–523, 1966.
Antonaccio MJ, Smith CB: Effects of chronic pretreatment with pargyline upon responses of the atrial pacemaker and of left atrial strips of guinea pigs to tyramine, mephentermine, d-amphetamine and adrenergic nerve stimulation. J Pharmacol Exp Ther (170): 97–107, 1969.
Jonason J: Prevention of the reserpine effect on rat salivary gland noradrenaline by inhibitors of monoamine oxidase and catechol-o-methyl transferase. J Pharm Pharmacol (22): 93–95, 1970.
Langley AE, Weiner N: The effect of pargyline pretreatment on the enhancement of the exocytotic release of norepinephrine during nerve stimulation which is induced by a benzoquinolizine compound with reserpine-like properties. J Pharmacol Exp Ther (213): 534–538, 1980.
Fairhurst AS, Whittaker ML, Ehlert FJ: Interactions of D600 (methoxyverapamil) and local anesthetics with rat brain α-adrenergic and muscarinic receptors. Biochem Pharmacol (29): 155–162, 1980.
Glossmann H, Hornung R: Calcium- and potassium-channel blockers interact with α-adrenoceptors. Mol Cell Endocrinol (19): 243–251, 1980.
Motulsky HJ, Snavely MD, Hughes RJ, Insel PA: Interaction of verapamil and other calcium channel blockers with α1- and α2-adrenergic receptors. Cir Res (52): 226–231, 1983.
Blackmore PF, El-Refai MF, Exton JH: α-Adrenergic blockade and inhibition of A23187 mediated Ca2+ uptake by the calcium antagonist verapamil in rat liver cells. Mol Pharmacol (15): 598–606, 1979.
Galzin A-M, Langer SZ: Presynaptic α2-adrenoceptor antagonism by verapamil but not by diltiazem in rabbit hypothalamic slices. Br J Pharmac (78): 571–577, 1983.
Bartholini G, Keller HH, Pletscher A: Effect of neuroleptics on endogenous norepinephrine in rat brain. Neuropharmacology (12): 751–756, 1973.
Wakade AR, Wakade TD: Reduction in norepinephrine content of sympathetic neuroeffector organs by alpha adrenergic antagonists and nerve stimulation: Evidence for presynaptic control of sympathetic transmitter release in intact animal. J Pharmacol Exp Ther (228): 287–292, 1984.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Chaudhry, A., Vohra, M.M. (1985). The Effect of Some Calcium-Channel Blocking Drugs on the Endogenous Catecholamine Content of Various Organs of the Rat. In: Beamish, R.E., Panagia, V., Dhalla, N.S. (eds) Pathogenesis of Stress-Induced Heart Disease. Developments in Cardiovascular Medicine, vol 46. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2589-5_17
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2589-5_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9623-2
Online ISBN: 978-1-4613-2589-5
eBook Packages: Springer Book Archive